BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan X, Moenster RP. Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series. Ther Adv Drug Saf 2019;11:2042098619862083. [PMID: 31312424 DOI: 10.1177/2042098619862083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Álvarez Otero J, Lamas Ferreiro JL, Sanjurjo Rivo A, de la Fuente Aguado J. Outpatient Parenteral Antimicrobial Therapy With Ceftolozane/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis. Open Forum Infect Dis 2020;7:ofaa409. [PMID: 33204747 DOI: 10.1093/ofid/ofaa409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Puzniak L, Dillon R, Palmer T, Collings H, Enstone A. Real-world use of ceftolozane/tazobactam: a systematic literature review. Antimicrob Resist Infect Control 2021;10:68. [PMID: 33832545 DOI: 10.1186/s13756-021-00933-8] [Reference Citation Analysis]
3 Maraolo AE, Mazzitelli M, Trecarichi EM, Buonomo AR, Torti C, Gentile I. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. Int J Antimicrob Agents 2020;55:105891. [PMID: 31923569 DOI: 10.1016/j.ijantimicag.2020.105891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]